Loading stock data…
ANL
$15.50+1.23 (+8.62%)
Market ClosedLast close May 1
Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Adlai Nortye Ltd. in the Healthcare sector is trading at $15.50. The stock is currently near its 52-week high of $17.25, remaining 252.3% above its 200-day moving average. Technical signals show neutral RSI of 60 and bearish MACD signal, explaining why ANL maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 60) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$15.50
Potential Upside
5%
Whystock Fair Value$16.28
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trials for the treatm...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$791.38M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.71
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-537.71%
Volume
Today's trading volume
587,672
Recent News
H.C. Wainwright Sees “Potential Best-in-Class Potency” for Adlai Nortye’s (ANL) Lead Asset, Lifts PT
Adlai Nortye Ltd. (NASDAQ:ANL) is one of the best performing small cap stocks so far in 2026. On April 20, H.C. Wainwright lifted the price target on Adlai Nortye Ltd. (NASDAQ:ANL) to $20 from $16 while maintaining a Buy rating on the shares. The firm told investors in a research note that the company’s lead […]
Adlai Nortye (ANL): 10 Tiny Stocks That Are On Fire Right Now
Adlai Nortye (NASDAQ:ANL) is one of the tiny stocks that are on fire right now. On April 16, Adlai Nortye entered into a securities purchase agreement for a private placement equity financing/PIPE expected to yield gross proceeds of ~$150 million. The oversubscribed transaction saw significant participation from a broad group of new and existing institutional […]
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?
Here is how ANI Pharmaceuticals (ANIP) and Adlai Nortye Ltd. Sponsored ADR (ANL) have performed compared to their sector so far this year.
Is Astellas Pharma (ALPMY) Stock Outpacing Its Medical Peers This Year?
Here is how Astellas Pharma Inc. (ALPMY) and Adlai Nortye Ltd. Sponsored ADR (ANL) have performed compared to their sector so far this year.
Adlai Nortye Ltd. Sponsored ADR (ANL) Upgraded to Buy: Here's Why
Adlai Nortye Ltd. Sponsored ADR (ANL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.